This exploratory analysis from the phase 3 INTRIGUE trial in pretreated, advanced GIST demonstrates the potential value of ctDNA next-generation sequencing (NGS)-based analysis of imatinib-resistant secondary KIT mutations to select second-line treatment. This evidence concerns the gene KIT and gastrointestinal stromal tumor.